Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

TrialNetworks Welcomes Global Pharmaceutical Industry Authority Jorge G. Guerra, MD as Advisory Board Chairman
  • USA - English


News provided by

TrialNetworks

Jan 16, 2014, 14:05 ET

Share this article

Share toX

Share this article

Share toX

Dr. Jorge Guerra
Dr. Jorge Guerra

Needham, MA (PRWEB) January 16, 2014 -- TrialNetworks continues to attract many of the most successful and progressive minds in clinical operations to help guide the strategic development of the industry’s only Clinical Trial Optimization System. Today the company announced pharmaceutical industry expert Jorge G. Guerra, MD has joined TrialNetworks as Chairman of the Advisory Board.

The more I was exposed to the power of the technology as a study sponsor, the more I realized that TrialNetworks is achieving something important with a system that is unique in both its scope and depth.

Post this

The TrialNetworks platform, which began as an innovative site engagement and communication portal, has rapidly grown into a comprehensive cloud-based solution for key aspects of a clinical trial from startup through closeout – including feasibility surveys, training, trial conduct efficiency, patient recruitment and retention, site activation, document management and more.

Dr. Guerra will play an instrumental role in identifying additional opportunities where the TrialNetworks platform can add real value within a clinical program by reducing timelines, improving quality and enabling collaboration between sponsors, sites, CROs and vendors.

During his successful research and business career spanning three decades in leadership roles at global biopharmaceutical companies (and current TrialNetworks customers) Merck & Co. and Biogen Idec, Dr. Guerra has established an unequaled reputation as an expert on the entire spectrum of clinical operation functions. He is especially experienced in core processes and activities such as clinical trial management, sponsor-site relationships, data management, medical writing, business and contract management, and operational excellence.

Said Dr. Guerra, “When I first became aware of TrialNetworks, I was intrigued by how sincerely the company shares my passion for solving real problems in clinical operations. The more I was exposed to the power of the technology as a study sponsor, the more I realized that TrialNetworks is achieving something important with a system that is unique in both its scope and depth. I am excited to contribute my industry knowledge and experience to help TrialNetworks design and develop pragmatic features that will standardize the platform as an essential tool for running efficient and high-quality trials with fully engaged and successful sites.”

Among his previous roles, Dr. Guerra served as Vice President, Clinical Research Operations - Global Trial Management at Merck & Co. During his twenty-four years at Merck, his major accomplishments included significant contributions to the execution of all development programs, particularly CRIXIVAN (indinavir), SINGULAIR (montelukast), CANCIDAS (caspofungin), INVANZ (ertapenem), COZAAR (losartan) and HYZAAR (losartan/HCTZ), JANUVIA (sitagliptin) & JANUMET (sitagliptin/metformin), and ISENTRESS (raltegravir).

As Senior Vice President, Global Clinical Development Operations at Biogen Idec, Dr. Guerra was responsible for clinical trial management, clinical data management, clinical business operations, medical writing, country management and field operations, operational excellence and Asia-Pacific strategy. He managed six simultaneous pivotal programs, four of which ended in regulatory filings, and successful FDA sponsor and site inspections, leading to approval of the blockbuster drug TECFIDERA (dimethyl fumarate). Coinciding with the end of his tenure, Biogen Idec was ranked as the top sponsor in CenterWatch’s 2013 Global Sponsor and Investigator Site Relationship Survey.

Previously, Dr. Guerra received his medical degree and trained in Internal Medicine at Universidad Peruana Cayetano Heredia in Lima, Peru. He completed his postgraduate training in Clinical Tropical Medicine and Medical Statistics & Epidemiology at the London School of Hygiene & Tropical Medicine. Before joining the pharmaceutical industry, he served as Associate Professor of Medicine and clinical investigator at his alma mater University Hospital. Dr. Guerra is also the author or co-author of 47 published articles and several book chapters.

Said Eric Silberstein, CEO of TrialNetworks, “We partner closely with customers every day to help us develop new features that push the conventional limits of how technology improves trial conduct. Having Jorge’s voice in the room adds a holistic perspective to everything we’re doing. His strategic expertise and hands-on insights will help us accelerate and achieve our mission of changing the way trials are run through the use of innovative technology.”

Dr. Guerra will chair an Advisory Board that also includes renowned pharmaceutical and technology experts Paul Bleicher, MD, PhD (CEO at Optum Labs), Ari Buchler (General Counsel and VP Corporate Development at Sophos), Esther Dyson (Chairman at EDventure and HICCup), Elliot Ehrich, MD (Sr. VP, R&D and Chief Medical Officer at Alkermes) and Ramy Mahmoud, MD, MPH (President and COO at OptiNose).

To discover how the TrialNetworks platform is revolutionizing clinical trial optimization, request a demo at http://www.trialnetworks.com.

About TrialNetworks
TrialNetworks, co-founded by U.S. Surgeon General nominee Dr. Vivek Murthy, provides sponsors and CROs the industry's only Clinical Trial Optimization System. Using this modern and intuitive technology, customers such as Merck & Co., Biogen Idec and Infinity Pharmaceuticals are able to transform the quality and efficiency of clinical operations at each stage of a trial from feasibility through closeout. TrialNetworks apps, including Checklist™, Training™, Document Library™, Visit Guide™, Action Items™ and Directory™, are available in a unified and secure cloud-based interface. Customers ranging from biotechs to Top-10 pharma companies have implemented the TrialNetworks platform for use in Phase I-IV trials by more than 25,000 site staff in 60 countries. To learn why sponsors and CROs rely on TrialNetworks to optimize clinical trial operations, request a guided online demo at http://www.trialnetworks.com.

Kristopher Sarajian, TrialNetworks, +1 6179524071 Ext: 132, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.